Anti-phospho-JAK2 (Tyr1007)(J02-65BR)

Anti-phospho-JAK2 (Tyr1007)(J02-65BR)

  • $325.00


Description :Rabbit Polyclonal Antibody

Species :

Tag :

Expression System:

Sequence :

Specificity :Recognizes the JAK2 protein phosphorylated at tyrosine 1007

Cited Applications :IHC

Cross Reactivity :Human, Mouse and Rat

Host / Isotype / Clone# :Rabbit, IgG

Immunogen :The antiserum was produced against synthesized phosphopeptide derived from human JAK2 around the phosphorylation site of tyrosine 1007 (K-E-YP-Y-K).

Purification :Affinity chromatography

Stability :Store at 4oC (add 0.1% NaN3) for several months, and at -20oC for longer periods. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Sample Data :Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Anti-phospho-JAK2 (Tyr1007).

Scientific Background :JAK2 is a member of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway (1). JAK2 has two near-identical phosphate-transferring domains. One domain exhibits the kinase activity while the other stabilizes the JAK conformational structure. JAK2 is the predominant JAK kinase activated in response to several growth factors and cytokines such as IL-3, GM-CSF and erythropoietin. JAK2 has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon (2).

References  :
1. Lacronique, V. Et al: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science, 1997; 278: 1309-1312.

2. Ho, J.M. et al: TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways. Blood, 2002; 100: 1438-1448.

3. James C, et al. (2005) Nature. 434(7037): 1144-1148. Argetsinger LS, et al. (2004) Mol Cell Biol. 24(11): 4955-4967.

4. Ungureanu D, et al. (2002) Mol Cell Biol. 22(10): 3316-3326. Xie S, et al. (2001) Oncogene. 20(43): 6188-6195.

Product Sheets (By Lot #) :


Research Areas :Cancer, Cardiovascular Disease, Cytoplasmic Tyrosine Kinases, Inflammation, JAK/STAT Pathway, Cancer, Inflammation, Cardiovascular Disease, JAK/STAT Pathway, Cytoplasmic Tyrosine Kinases